Interview with Hannah Pendergraff, PhD
I became interested in oligo therapeutics when I started working in David Corey’s lab. I joined his group in 2009...
Interview with Keith T. Gagnon, PhD
I was thrown into the world of nucleic acid therapeutics during my postdoc with David Corey. Â My Ph.D. training focused on the...
Interview with Paul Burke, PhD
Paul Burke, PhD Principal, Burke Bioventures LLC How did you become interested in the field of oligonucleotides? I first became interested in
Interview with Kotaro Yoshioka, MD, PhD
Kotaro Yoshioka, MD, PhD Department of Neurology and Neurological Science, Tokyo Medical and Dental University How did you become interested in the field of
2017 Paper of the Year Award Winner: Richard Finkel, MD
Richard Finkel, MD Nemours Children’s Hospital Talk Title: Treatment of Infantile-onset Spinal Muscular Atrophy with Nusinersen: a Phase 2, Open-label, Dose-escalation Study Biography: Richard S. Finkel, MD is Professor of Neurology at the University of Central Florida School of Medicine, and Chief, Division of Neurology ...
2017 Gewirtz Memorial Scholarship Winner: Karyn Schmidt, PhD
Karyn Schmidt, PhDDana-Farber Cancer InstituteTalk Title: Inhibiting the Androgen Receptor Interaction with the Long Non-Coding RNA SLNCR using 2’-FANA-Modified Oligonucleotides Decreases Melanoma Invasion and Proliferation.Biography: Karyn Schmidt received her PhD in Biochemistry from the University of Rochester in 2013, where she studied in the laboratory of J. ...
Interview with Thorleif Møller, PhD
ThorleifMøller, PhD Mirrx Therapeutics A/S CEO & Founder How did you become interested in the field of oligonucleotides? During my PhD studies at the
2017 OTS Young Investigator Award Winner Keith Gagnon, Ph.D.
Keith Gagnon, PhD. Southern Illinois University Talk Title: A ‘Guided’ Tour of an Early Career in RNA and Nucleic Acid Therapeutics Biography: Dr. Keith T. Gagnon earned his Ph.D. from NC State University under the direction of Dr. E. Stuart Maxwell. His thesis investigated the ...
Interview with Sebastien Burel, PhD
Sebastien Burel, PhD Ionis Pharmaceuticals Director Nonclinical Development How did you become interested in the field of oligonucleotides? Mostly by accident.
